Nevro (NVRO) M&A Announcement summary

Deal rationale and strategic fit

• Expands Globus Medical's reach into chronic pain treatment and neuromodulation markets, supporting its goal to be a leading musculoskeletal technology company.

• Access to Nevro's differentiated technologies and global infrastructure enhances future growth and diversification in pain management.

Financial terms and conditions

• All-cash transaction at $5.85 per Nevro share, valuing Nevro at approximately $250 million.

• Represents a 27% premium to 90-day VWAP, 38% to 30-day VWAP, and 17% to Nevro's closing price on Feb 5, 2025.

• Transaction expected to close late Q2 2025, subject to shareholder and regulatory approvals.

Synergies and expected cost savings

• Globus Medical expects to optimize Nevro's financial performance and drive enhanced profitability through scale and operational discipline.

• Acquisition anticipated to be accretive to Globus Medical's earnings in the second year post-close.